Share-based Payment Arrangement, Expense of ENZO BIOCHEM INC from 31 Jan 2012 to 30 Apr 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ENZO BIOCHEM INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Jan 2012 to 30 Apr 2025.
  • ENZO BIOCHEM INC Share-based Payment Arrangement, Expense for the quarter ending 30 Apr 2025 was $174,000, a 16% decline year-over-year.
  • ENZO BIOCHEM INC annual Share-based Payment Arrangement, Expense for 2023 was $2,268,000, a 52% increase from 2022.
  • ENZO BIOCHEM INC annual Share-based Payment Arrangement, Expense for 2022 was $1,496,000, a 65% increase from 2021.
  • ENZO BIOCHEM INC annual Share-based Payment Arrangement, Expense for 2021 was $907,000, a 2.8% decline from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ENZO BIOCHEM INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $174,000 -$33,000 -16% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q3
Q4 2024 $181,000 -$80,000 -31% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q2
Q3 2024 $171,000 -$904,000 -84% 01 Aug 2024 31 Oct 2024 10-Q 16 Dec 2024 2025 Q1
Q1 2024 $2,690,000 $207,000 -$281,000 -58% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q3
Q4 2023 $2,971,000 $261,000 -$174,000 -40% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q2
Q3 2023 $3,145,000 $1,075,000 +$877,000 +443% 01 Aug 2023 31 Oct 2023 10-Q 16 Dec 2024 2025 Q1
Q2 2023 $2,268,000 $1,147,000 +$708,000 +161% 01 May 2023 31 Jul 2023 10-K 03 Nov 2023 2023 FY
Q1 2023 $1,560,000 $488,000 +$326,000 +201% 01 Feb 2023 30 Apr 2023 10-Q 13 Jun 2024 2024 Q3
Q4 2022 $1,234,000 $435,000 -$244,000 -36% 01 Nov 2022 31 Jan 2023 10-Q 13 Mar 2024 2024 Q2
Q3 2022 $1,478,000 $198,000 -$18,000 -8.3% 01 Aug 2022 31 Oct 2022 10-Q 15 Dec 2023 2024 Q1
Q2 2022 $1,496,000 $439,000 +$172,000 +64% 01 May 2022 31 Jul 2022 10-K 03 Nov 2023 2023 FY
Q1 2022 $1,324,000 $162,000 -$135,000 -45% 01 Feb 2022 30 Apr 2022 10-Q 09 Jun 2022 2022 Q3
Q4 2021 $1,459,000 $679,000 +$503,000 +286% 01 Nov 2021 31 Jan 2022 10-Q 14 Mar 2022 2022 Q2
Q3 2021 $956,000 $216,000 +$49,000 +29% 01 Aug 2021 31 Oct 2021 10-Q 12 Dec 2022 2023 Q1
Q2 2021 $907,000 $267,000 +$62,000 +30% 01 May 2021 31 Jul 2021 10-K 14 Oct 2022 2022 FY
Q1 2021 $845,000 $297,000 +$90,000 +43% 01 Feb 2021 30 Apr 2021 10-Q 09 Jun 2022 2022 Q3
Q4 2020 $755,000 $176,000 -$126,000 -42% 01 Nov 2020 31 Jan 2021 10-Q 14 Mar 2022 2022 Q2
Q3 2020 $881,000 $167,000 -$52,000 -24% 01 Aug 2020 31 Oct 2020 10-Q 15 Dec 2021 2022 Q1
Q2 2020 $933,000 $205,000 +$83,000 +68% 01 May 2020 31 Jul 2020 10-K 14 Oct 2022 2022 FY
Q1 2020 $850,000 $207,000 -$84,000 -29% 01 Feb 2020 30 Apr 2020 10-Q 11 Jun 2021 2021 Q3
Q4 2019 $934,000 $302,000 +$11,000 +3.8% 01 Nov 2019 31 Jan 2020 10-Q 16 Mar 2021 2021 Q2
Q3 2019 $923,000 $219,000 -$16,000 -6.8% 01 Aug 2019 31 Oct 2019 10-Q 11 Dec 2020 2021 Q1
Q2 2019 $939,000 $122,000 01 May 2019 31 Jul 2019 10-K 12 Oct 2021 2021 FY
Q1 2019 $291,000 +$87,000 +43% 01 Feb 2019 30 Apr 2019 10-Q 09 Jun 2020 2020 Q3
Q4 2018 $291,000 +$83,000 +40% 01 Nov 2018 31 Jan 2019 10-Q 06 Mar 2020 2020 Q2
Q3 2018 $235,000 +$30,000 +15% 01 Aug 2018 31 Oct 2018 10-Q 10 Dec 2019 2019 Q1
Q1 2018 $204,000 -$5,000 -2.4% 01 Feb 2018 30 Apr 2018 10-Q 10 Jun 2019 2019 Q3
Q4 2017 $208,000 -$33,000 -14% 01 Nov 2017 31 Jan 2018 10-Q 11 Mar 2019 2019 Q2
Q3 2017 $205,000 +$54,000 +36% 01 Aug 2017 31 Oct 2017 10-Q 10 Dec 2018 2019 Q1
Q1 2017 $209,000 +$60,000 +40% 01 Feb 2017 30 Apr 2017 10-Q 11 Jun 2018 2018 Q3
Q4 2016 $241,000 +$131,000 +119% 01 Nov 2016 31 Jan 2017 10-Q 12 Mar 2018 2018 Q2
Q3 2016 $151,000 +$40,000 +36% 01 Aug 2016 31 Oct 2016 10-Q 07 Dec 2017 2018 Q1
Q1 2016 $149,000 +$36,000 +32% 01 Feb 2016 30 Apr 2016 10-Q 08 Jun 2017 2017 Q3
Q4 2015 $110,000 +$5,000 +4.8% 01 Nov 2015 31 Jan 2016 10-Q 13 Mar 2017 2017 Q2
Q3 2015 $111,000 +$13,000 +13% 01 Aug 2015 31 Oct 2015 10-Q 08 Dec 2016 2017 Q1
Q1 2015 $113,000 -$170,000 -60% 01 Feb 2015 30 Apr 2015 10-Q 08 Jun 2016 2016 Q3
Q4 2014 $105,000 -$4,000 -3.7% 01 Nov 2014 31 Jan 2015 10-Q 09 Mar 2016 2016 Q2
Q3 2014 $98,000 -$5,000 -4.9% 01 Aug 2014 31 Oct 2014 10-Q 08 Dec 2015 2015 Q1
Q1 2014 $283,000 +$143,000 +102% 01 Feb 2014 30 Apr 2014 10-Q 09 Jun 2015 2015 Q3
Q4 2013 $109,000 -$51,000 -32% 01 Nov 2013 31 Jan 2014 10-Q 12 Mar 2015 2015 Q2
Q3 2013 $103,000 -$39,000 -27% 01 Aug 2013 31 Oct 2013 10-Q 09 Dec 2014 2015 Q1
Q1 2013 $140,000 -$28,000 -17% 01 Feb 2013 30 Apr 2013 10-Q 09 Jun 2014 2014 Q3
Q4 2012 $160,000 -$57,000 -26% 01 Nov 2012 31 Jan 2013 10-Q 11 Mar 2014 2014 Q2
Q3 2012 $142,000 01 Aug 2012 31 Oct 2012 10-Q 10 Dec 2013 2014 Q1
Q1 2012 $168,000 01 Feb 2012 30 Apr 2012 10-Q 10 Jun 2013 2013 Q3
Q4 2011 $217,000 01 Nov 2011 31 Jan 2012 10-Q 12 Mar 2013 2013 Q2

ENZO BIOCHEM INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $2,268,000 +$772,000 +52% 01 Aug 2022 31 Jul 2023 10-K 03 Nov 2023 2023 FY
2022 $1,496,000 +$589,000 +65% 01 Aug 2021 31 Jul 2022 10-K 03 Nov 2023 2023 FY
2021 $907,000 -$26,000 -2.8% 01 Aug 2020 31 Jul 2021 10-K 14 Oct 2022 2022 FY
2020 $933,000 -$6,000 -0.64% 01 Aug 2019 31 Jul 2020 10-K 14 Oct 2022 2022 FY
2019 $939,000 01 Aug 2018 31 Jul 2019 10-K 12 Oct 2021 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.